Table 1 Re-calculation of a meta-analysis of CVD mortality due to use of AST first presented by Nguyen et al18

From: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

  

AST

Control

 

Risk ratio

Study

Median AST duration (months)

Events

Total

Events

Total

Weight (%)

M-H, Random, 95%CI

D’Amico et al, 2008

6

13

102

13

104

15.1

1.02 (0.50, 2.09)

Bolla et al, 2010

36

22

207

17

208

21.4

1.30 (0.71, 2.38)

Roach et al, 2008

4

31

224

26

232

32.7

1.23 (0.76, 2.01)

Denham et al, 2011

3–6

36

532

23

270

30.8

0.79 (0.48, 1.31)

Total (95% CI)

  

1065

 

814

 

1.06 (0.80,1.40)

Total events

 

102

 

79

   
  1. Heterogeneity: I2=0% (P=0.55)
  2. Test for overall effect: Z=0.40 (P=0.69)
Back to article page